Earthtimes, UK - Mar 13, 2008 As part of the alliance, Genzyme became a preferred development partner for Isis for programs in CNS and certain rare diseases. * Isis licensed two type 2 ... |
By Cancer
3859 items (3859 unread) in 83 feeds
Click on blue folders to expand
Adrenal Gland Cancer
(421)
Ampulla Of Vater
(26)
Anal Cancer
(261)
Angiosarcoma
(65)
Appendix Cancer
(33)
Bile Duct Cancer
(510)
Brain & CNS
(736)
Carcinoid
(157)
Endocrine/Neuroendocrine
(253)
Gall Bladder Cancer
(85)
General
(108)
Hemangioendothelioma
(28)
HemeOnc
(431)
Hepatoblastoma
(59)
Pancreas
(47)
Phyllodes
(12)
Rhabdomyosarcoma
(205)
Sarcoma
(283)
Google - Rare CNS Tumor (13 unread)
-
Isis Reports Financial Results and Highlights for Fiscal year 2007 - Earthtimes
Posted: March 13th, 2008, 5:11am EDT
-
Isis Reports Financial Results and Highlights for Fiscal year 2007 - Earthtimes
Posted: March 13th, 2008, 5:11am EDT
Isis Reports Financial Results and Highlights for Fiscal year 2007
Earthtimes, UK - Mar 13, 2008
As part of the alliance, Genzyme became a preferred development partner for Isis for programs in CNS and certain rare diseases. * Isis licensed two type 2 ... -
Isis Reports Financial Results and Highlights for Fiscal year 2007 - PR Newswire (press release)
Posted: March 13th, 2008, 5:09am EDT
Isis Reports Financial Results and Highlights for Fiscal year 2007
PR Newswire (press release), NY - Mar 13, 2008
As part of the alliance, Genzyme became a preferred development partner for Isis for programs in CNS and certain rare diseases. * Isis licensed two type 2 ... -
Anavex 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre ... - Newswire Today (press release)
Posted: March 11th, 2008, 10:20am EDT
Anavex 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre ...
Newswire Today (press release), UK - Mar 11, 2008
The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare ... -
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ... - Earthtimes
Posted: March 10th, 2008, 8:09am EDT
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ...
Earthtimes, UK - 12 hours ago
The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare ... -
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ... - Earthtimes
Posted: March 10th, 2008, 8:09am EDT
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ...
Earthtimes, UK - Mar 10, 2008
The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare ... -
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ... - Genetic Engineering News (press release)
Posted: March 10th, 2008, 7:32am EDT
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ...
Genetic Engineering News (press release), NY - Mar 10, 2008
The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare ... -
Anavex 7-1037 Reduces Rate of Cancer Tumor Growth 69% in ... - PharmaLive.com (press release)
Posted: March 10th, 2008, 7:24am EDT
Anavex 7-1037 Reduces Rate of Cancer Tumor Growth 69% in ...
PharmaLive.com (press release), PA - Mar 10, 2008
The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare ... -
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ... - PR Newswire (press release)
Posted: March 10th, 2008, 7:11am EDT
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ...
PR Newswire (press release), NY - Mar 10, 2008
The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare ... -
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ... - CNNMoney.com (press release)
Posted: March 10th, 2008, 7:09am EDT
Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre ...
CNNMoney.com (press release) - Mar 10, 2008
The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering from clear cell sarcoma. Clear cell sarcoma is a rare ... -
Acute and Chronic Lyme Disease: Controversies for Neuropsychiatry - Journal of Neuropsychiatry (subscription)
Posted: February 27th, 2008, 4:37pm EST
Acute and Chronic Lyme Disease: Controversies for Neuropsychiatry
Journal of Neuropsychiatry (subscription) - Feb 27, 2008
One diagnostic challenge in evaluation of central nervous system disease is differentiation of inflammatory lesions from tumor. ... -
Acute and Chronic Lyme Disease: Controversies for Neuropsychiatry - Journal of Neuropsychiatry (subscription)
Posted: February 27th, 2008, 4:37pm EST
Acute and Chronic Lyme Disease: Controversies for Neuropsychiatry
Journal of Neuropsychiatry (subscription) - Feb 27, 2008
One diagnostic challenge in evaluation of central nervous system disease is differentiation of inflammatory lesions from tumor. ... -
High-dose Methotrexate Provides Long-term Results in Central ... - Cancer Consultants
Posted: February 19th, 2008, 10:15am EST
High-dose Methotrexate Provides Long-term Results in Central ...
Cancer Consultants, ID - Feb 19, 2008
Primary brain lymphoma is a relatively rare brain tumor which appears to be increasing in incidence. In the past, primary brain lymphomas have been treated ...